Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Common Equity (2016 - 2025)

iBio (IBIO) has disclosed Common Equity for 15 consecutive years, with $56.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 307.05% to $56.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.6 million, a 307.05% increase, with the full-year FY2025 number at $14.9 million, down 30.22% from a year prior.
  • Common Equity was $56.6 million for Q4 2025 at iBio, up from $56.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $108.6 million in Q2 2021 to a low of $9.2 million in Q4 2023.
  • A 5-year average of $44.3 million and a median of $23.1 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 2549.23% in 2021, then crashed 79.22% in 2022.
  • iBio's Common Equity stood at $90.6 million in 2021, then plummeted by 79.22% to $18.8 million in 2022, then plummeted by 51.14% to $9.2 million in 2023, then skyrocketed by 51.08% to $13.9 million in 2024, then surged by 307.05% to $56.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Common Equity are $56.6 million (Q4 2025), $56.0 million (Q3 2025), and $14.9 million (Q2 2025).